Skip to main content

Table 1 Baseline characteristics of lenalidomide-treated patients by age group

From: Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Characteristic

<65 years

(n = 97)a

≥65 to <75 years

(n = 98)

≥75 years

(n = 91)

Age, years

 Median

59

69

79

 Range

36–64

65–74

75–95

Female sex, n (%)

71 (73.2)†

56 (57.1)‡

72 (79.1)

Time since diagnosis, years

 Median

2.4

2.7

2.5

 Range

0.2–20.7

0.2–14.7

0.1–29.2

Creatinine clearance, ml/min

 Median

117.3

88.6

55.5

 Range

49.5–259.0

32.3–162.4

18.2–95.6

ECOG performance status score,§ n (%)

 0

17 (17.5)

31 (31.6)

11 (12.1)

 1

23 (23.7)

22 (22.4)

30 (33.0)

 2

3 (3.1)

3 (3.1)

8 (8.8)

 Missingb

54 (55.7)

42 (42.9)

42 (46.2)

IPSS risk, n (%)

 Low

25 (30.5)**

36 (43.9)

37 (45.7)

 Intermediate-1

53 (64.6)

37 (45.1)

39 (48.1)

 Intermediate-2

4 (4.9)

6 (7.3)

5 (6.2)

 High

0

3 (3.7)

0

 Missing

15 (15.5)

16 (16.3)

10 (11.0)

IPSS-R risk, n (%)

 Very low

0

1 (1.3)

1 (1.3)

 Low

32 (43.2)

30 (38.5)

41 (54.7)

 Intermediate

33 (44.6)

35 (44.9)

22 (29.3)

 High

8 (10.8)

8 (10.3)

8 (10.7)

 Very high

1 (1.4)

4 (5.1)

3 (4.0)

 Missing

23 (23.7)

20 (20.4)

16 (17.5)

Cytogenetic abnormalities, n (%)

 Isolated del(5q)

63 (64.9)

76 (77.6)

61 (67.0)

 del(5q) plus 1 additional abnormality

22 (22.7)

11 (11.2)

17 (18.7)

 del(5q) plus ≥2 additional abnormalities

8 (8.2)

5 (5.1)

11 (12.1)

 Other or missing data

4 (4.1)

6 (6.1)

2 (2.2)

Number of cytopenias, n (%)

 1

50 (51.5)

60 (61.2)

56 (61.5)

 2 or 3

47 (48.5)

38 (38.8)

34 (37.4)

 Missing

0

0

1 (1.1)c

RBC transfusion burden, units/8 weeks

 Median

6

6

6

 Range

1–15

1–25

1–12

Hemoglobin level, g/dl

 Median

7.4‡‡

7.8

7.9

 Range

4.3–10.0

4.0–10.4

3.6–11.8

Platelet count, ×109/l

 <150

23 (23.7)

32 (32.7)

29 (31.9)

 ≥150

74 (76.3)

66 (67.3)

62 (68.1)

ANC, ×109/l

 Median

1.9

2.1

2.1

 Range

0.2–21.0

0.4–10.3

0.3–20.7

Bone marrow blasts, %

 Median

3.0

4.0

2.0

 Range

0.0–49.0

0.0–19.0

0.0–17.0

p53 protein overexpression in ≥1% cells, n/N (%)

11/34 (32.4)

8/22 (36.4)

11/29 (37.9)

  1. ANC absolute neutrophil count, ECOG Eastern Cooperative Oncology Group, IPSS International Prognostic Scoring System, IPSS-R IPSS–revised, RBC red blood cell
  2. † p = 0.024 vs. ≥65 to <75 years; ‡ p = 0.002 vs. ≥75 years; § p = 0.001 for ≥65 to <75 years vs. ≥75 years; **p = 0.035 vs. ≥65 to <75 years; ‡‡ p = 0.006 vs. ≥65 to <75 years; p = 0.003 vs. ≥75 years despite intermittent/recent RBC transfusions
  3. aOne patient in the <65 years group was later diagnosed with acute myeloid leukemia, which had been present at the start of the study
  4. bThe ECOG performance status score could only be determined for patients with this information entered into the study database
  5. cThe number of cytopenias at baseline could not be determined for one patient due to missing ANC data
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us